Pictet North America Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Pictet North America Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-17,385	Closed	-$39K	–	129
2020 Q3	$39K	Hold	17,385	–	–	0.01%	122
2020 Q2	$62K	Hold	17,385	–	–	0.01%	124
2020 Q1	$66K	Hold	17,385	–	–	0.01%	135
2019 Q4	$52K	Buy	+17,385	New	+$45.2K	0.01%	156

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Pictet North America Advisors's BMY.RT Position: Q4 2020 in Review

Pictet North America Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 17,385 shares — an estimated $39K sold.

Pictet North America Advisors first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $66K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Pictet North America Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Pictet North America Advisors sold 17,385 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $39K.
Pictet North America Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Pictet North America Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $66K in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Pictet North America Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.